Spots Global Cancer Trial Database for elranatamab
Every month we try and update this database with for elranatamab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | NCT06152575 | Multiple Myelom... | Elranatamab Elotuzumab Pomalidomide Dexamethasone Bortezomib Carfilzomib | 18 Years - | Pfizer | |
| Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) | NCT05238311 | Multiple Myelom... | Elranatamab | 18 Years - | Pfizer | |
| MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | NCT05020236 | Multiple Myelom... | Elranatamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | NCT05927571 | Relapsed or Ref... | Cevostamab Elranatamab Tocilizumab | 18 Years - | Genentech, Inc. | |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | NCT06215118 | Multiple Myelom... | Elranatamab Iberdomide | 18 Years - | Pfizer | |
| Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | NCT06421675 | Refractory Mult... | Elranatamab inj... | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma | NCT06183489 | Smoldering Mult... | Elranatamab | 18 Years - | Stichting European Myeloma Network | |
| Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | NCT06207799 | Multiple Myelom... Post-transplant... Pre-transplant ... | Elranatamab Lenalidomide Plerixafor Melphalan Busulfan G-CSF Stem cell trans... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Self-administration of Subcutaneous Elranatamab in the Patients' Homes. | NCT06015542 | Multiple Myelom... | Elranatamab | 18 Years - | Odense University Hospital | |
| MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb | NCT04649359 | Multiple Myelom... | Elranatamab (PF... | 18 Years - | Pfizer | |
| Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma | NCT06183489 | Smoldering Mult... | Elranatamab | 18 Years - | Stichting European Myeloma Network | |
| A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma | NCT05932290 | Multiple Myelom... | Elranatamab Standard of car... | 18 Years - | Pfizer | |
| Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes | NCT06282978 | Multiple Myelom... | Elranatamab (PF... | 18 Years - | PETHEMA Foundation | |
| A Real-World Study of Bispecific Antibodies in Multiple Myeloma | NCT06359067 | Multiple Myelom... | Treated by bisp... Not treated by ... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Real-World Study of Bispecific Antibodies in Multiple Myeloma | NCT06359067 | Multiple Myelom... | Treated by bisp... Not treated by ... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | NCT05020236 | Multiple Myelom... | Elranatamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Pfizer | |
| Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | NCT06421675 | Refractory Mult... | Elranatamab inj... | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) | NCT06057402 | Multiple Myelom... | Elranatamab | 18 Years - | Pfizer | |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | NCT05675449 | Multiple Myelom... | Elranatamab Carfilzomib Maplirpacept | 18 Years - | Pfizer | |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant | NCT05623020 | Multiple Myelom... | Elranatamab Daratumumab Lenalidomide Dexamethasone | 18 Years - | Pfizer | |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | NCT05675449 | Multiple Myelom... | Elranatamab Carfilzomib Maplirpacept | 18 Years - | Pfizer | |
| Self-administration of Subcutaneous Elranatamab in the Patients' Homes. | NCT06015542 | Multiple Myelom... | Elranatamab | 18 Years - | Odense University Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
